More than a million people in England who are at high risk of heart attacks and strokes will soon be offered the weight-loss jab Wegovy for free on the National Health Service (NHS), following a landmark recommendation from the country’s top health authorities. The move, which was announced at the end of March 2026, marks a significant expansion of access to semaglutide—the active ingredient in Wegovy and Ozempic—and could transform cardiovascular care for those most vulnerable to life-threatening events.
Wegovy is already known to many as a weight-loss treatment, but recent clinical trials have revealed its benefits go far beyond trimming waistlines. According to the National Institute for Health and Care Excellence (NICE), the NHS’s drug price watchdog, semaglutide can reduce the risk of major cardiovascular emergencies—including heart attacks and strokes—even before patients experience significant weight loss. This suggests the drug acts directly on the heart and blood vessels, offering a new layer of protection for people who have already suffered a heart attack, stroke, or serious circulation problem in their legs.
Eligibility for the new NHS program will focus on adults with a Body Mass Index (BMI) of 27 or higher who have a history of cardiovascular disease. This includes those who have previously experienced a heart attack, stroke, or severe complications from peripheral arterial disease. The NHS estimates that about 1.2 million people in England could benefit from this expanded access, with similar guidance expected to apply in Wales. The rollout is set to begin this summer, with patients able to self-administer the drug at home using a weekly pen injector.
“We know that people who have already had a heart attack or stroke are living with real fear that it could happen again,” said Helen Knight, director of medicines evaluation at NICE, in a statement reported by The Guardian. “The evidence from the clinical trial is compelling. It showed that people taking semaglutide alongside their existing heart medicines were significantly less likely to have another heart attack or stroke. Today’s decision gives thousands of people in that situation an extra layer of protection, on top of the medicines they are already taking.”
The new guidance is built on the results of large-scale clinical trials. Notably, a study led by University College London (UCL) and published in The Lancet found that semaglutide reduced the risk of heart attack or stroke by about 20% compared to a placebo, regardless of how much weight patients lost. The findings were so robust that experts now consider these so-called “weight loss drugs” to be vital medicines for preventing deadly cardiovascular events, rather than simply tools for slimming down.
Dr Sonya Babu-Narayan, clinical director at the British Heart Foundation, echoed this sentiment in a statement: “So-called ‘weight loss drugs’ like semaglutide have proven benefits beyond reducing the number on the scales—they are now considered important medicines for preventing deadly heart attacks and strokes. Today’s guidance will no doubt help save lives as cardiovascular disease is still one of the country’s biggest killers. That’s why it’s so important that new and effective medicines which prevent cardiovascular disease complications, like semaglutide, get to everyone who could benefit as soon as possible.”
For patients, the process will involve more than just a simple injection. NICE and NHS England have emphasized that Wegovy should be prescribed alongside a healthy diet and regular physical activity, and in addition to existing medicines such as statins or anti-hypertensive drugs. This holistic approach is aimed at maximizing the benefits while minimizing potential risks. Some side effects, such as bloating, nausea, or discomfort, may occur, and doctors are advised to monitor patients closely.
The significance of this move isn’t lost on policymakers or medical professionals. Sharon Hodgson, the health minister, called the availability of weight-loss drugs for those at risk of heart attacks and strokes a “gamechanger” and a “lifesaver.” Helen Williams, NHS England’s clinical director for cardiovascular disease prevention, described the new treatment option as potentially “life-changing,” saying, “Used alongside a healthy diet and regular exercise, semaglutide could help prevent thousands of future major cardiovascular events and give many people the chance at a longer and healthier life.”
From a scientific perspective, the mechanism behind semaglutide’s remarkable effects is tied to its ability to mimic the hormone GLP-1, which makes people feel fuller and slows down digestion. But the early benefits seen in trials—before significant weight loss—point to a more direct impact on cardiovascular health. As NICE explains, these results reflect a growing body of evidence that GLP-1 receptor agonists, the class of drugs to which semaglutide belongs, offer benefits extending well beyond weight loss.
Novo Nordisk, the Danish pharmaceutical company that manufactures Wegovy, saw its shares rise following the NICE recommendation, according to CNBC. The company has also launched new versions of Wegovy, including an oral pill and higher-dose formulations, as it faces competition from U.S.-based rival Eli Lilly. With about one in four adults in the UK living with obesity and heart and circulatory diseases remaining a leading cause of early death, the stakes for effective, accessible treatments couldn’t be higher.
The NHS’s agreement with Novo Nordisk ensures that the drug will be provided in a cost-effective manner, addressing concerns about the financial sustainability of such a large-scale rollout. However, questions remain about the long-term risks of semaglutide, as treatment is currently limited to two years on the NHS and ongoing studies will be needed to assess potential side effects over a longer period. Some experts, including Professor Robert Storey of the University of Sheffield, have warned that GLP-1 drugs could reduce muscle mass as well as fat, underscoring the importance of physical activity—especially resistance training—to counteract any negative effects on muscle strength.
While the NICE guidance is currently in draft form, NHS England officials have assured that the new eligible group will be able to access the drug “within months.” The decision has been widely welcomed by medical professionals, with Professor Naveed Sattar of the University of Glasgow describing it as “very good news” that stems from high-quality trial evidence. Professor Riyaz Patel of UCL called the development “really exciting” for both patients and doctors, though he cautioned that the NHS will need to ensure it has the capacity to deliver the treatment to everyone who qualifies.
For now, the expansion of Wegovy’s use on the NHS represents a hopeful turning point in the fight against heart disease and stroke in England. With a combination of scientific rigor, patient advocacy, and public health commitment, the country is taking bold steps to give those at greatest risk a better shot at a longer, healthier life.